• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders

    2/26/26 12:00:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $REGN alert in real time by email

    Key Takeaways:

    • Regeneron will extend its title sponsorship of the Regeneron Science Talent Search (STS) for a second decade, continuing its partnership with Society for Science to support the United States' oldest and most prestigious science and mathematics competition for high school seniors
    • Since the start of Regeneron's sponsorship in 2017 through this year's STS, Regeneron and the Society have engaged and inspired more than 20,000 of the nation's top young scientists, recognized 3,000 as Regeneron scholars, and awarded over $31 million in prizes
    • Regeneron is also the title sponsor of the Regeneron International Science and Engineering Fair (ISEF), a program of Society for Science and the world's largest high school science competition
    • Today's commitment brings Regeneron's total STS and ISEF investment, from 2017 to 2036, to more than $300 million

    TARRYTOWN, N.Y. and WASHINGTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Society for Science (the Society) announced the renewal of Regeneron's title sponsorship of the Regeneron Science Talent Search (STS), the United States' oldest and most prestigious science and mathematics competition for high school seniors. The company is increasing its commitment for the next 10 years by 50%, pledging an additional $150 million to further empower and inspire the next generation of science and technology leaders, and bringing its 20-year investment in STS to $250 million. Regeneron is also the title sponsor of the Regeneron International Science and Engineering Fair (ISEF), a program of the Society and the world's largest high school science competition. Regeneron's support for these two premier programs totals more than $300 million from 2017 to 2036.

    "My own scientific journey can be traced back to my experience with the Science Talent Search, which profoundly shaped who I am today. Participating in and becoming a winner of STS gave me the confidence to dedicate my life to science and the pursuit of inventing medicines that improve people's lives," said George D. Yancopoulos, M.D., Ph.D., co-Founder, co-Chairman, President, and Chief Scientific Officer at Regeneron, and a 1976 STS Winner. "Today, Regeneron helps millions of people around the world facing serious diseases, which is a testament to what is possible when young scientific talent is nurtured. We are renewing our commitment to STS because we see in these students that same potential to transform our world, and we eagerly await their future contributions to science and humanity."

    "At Regeneron, our success has always been driven by a deep belief in science and the people behind it," said Leonard S. Schleifer, M.D., Ph.D., co-Founder, co-Chairman, President, and Chief Executive Officer at Regeneron, and 1970 STS Alumnus. "This renewed, long-term investment in the Regeneron Science Talent Search – alongside our support for many other STEM education programs – reflects our confidence in the extraordinary potential of young scientists and our responsibility to help cultivate the curiosity, rigor and leadership that will shape the future of scientific discovery."

    What is the Regeneron Science Talent Search?

    The Regeneron Science Talent Search, first established in 1942 as the Westinghouse Science Talent Search and later the Intel Science Talent Search, is now proudly supported by Regeneron as its third long-term sponsor. Since the beginning of this enduring sponsorship through this year's STS, Regeneron and the Society have engaged and inspired more than 20,000 of the nation's top young scientists, recognized 3,000 as Regeneron scholars, and awarded over $31 million in prizes.

    For 85 years, STS has recognized and championed the United States' most promising young scientists whose groundbreaking research and leadership potential can fuel the breakthroughs of tomorrow. The competition serves as a catalyst for young scientists to build confidence, strengthen their research skills, and deepen their commitment to high-quality scientific inquiry.

    "In its 85th year, the Science Talent Search inspires and elevates the nation's top high school students passionate about tackling the world's most intractable problems," said Maya Ajmera, President and CEO at Society for Science; Executive Publisher, Science News; and 1985 STS Alumna. "This renewal not only secures the legacy of this historic competition but also amplifies its impact in the years ahead. With Regeneron's unwavering support, we will continue to empower the extraordinary – the rising stars and the legends in the making – who will define the future of science, innovation, and discovery."

    Each year, nearly 2,500 of the nation's top science and math students from across the United States enter STS, presenting original research spanning fields such as artificial intelligence, climate science, cancer biology, and renewable energy. Thousands of STS alumni have gone on to world-changing careers in science, with several earning esteemed honors, including the Nobel Prize, the Fields Medal, the National Medal of Science, and the MacArthur Fellowship for groundbreaking research across STEM fields. Since Regeneron became the title sponsor, entries to STS have increased by 49%, reflecting a significant expansion in the program's reach and impact on young scientists nationwide.

    As part of this sponsorship renewal, Regeneron will continue to support the Society's STEM Outreach Programs. Through these programs, the Society works to provide high-quality educator training and reach young people across the country – in every state, including both urban and rural areas, and regardless of socioeconomic status, gender, or race – to help all students reach their full potential through STEM.

    Regeneron's STS and ISEF sponsorships are a cornerstone of STEM-Fueled™, the company's collection of longstanding programs and partnerships that fuel the next generation of scientific innovators to pursue bold ideas and advance world-changing solutions. Through philanthropic investments, Regeneron has provided more than 4 million students with STEM experiences since 2020.

    What is Regeneron?

    Regeneron (NASDAQ:REGN) is a leading biotechnology company that invents, develops, and commercializes potentially life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases.

    Regeneron believes that operating as a good corporate citizen is crucial to delivering on our mission. We approach corporate responsibility with three goals in mind: to improve the lives of people with serious diseases, to foster a culture of integrity and excellence, and to build sustainable communities. Our most significant philanthropic investments are in science education, a commitment we call STEM-Fueled™ – our collection of programs and partnerships, including the Regeneron Science Talent Search (STS) and the Regeneron International Science and Engineering Fair (ISEF), that fuel future scientific innovators to pursue bold ideas and advance world-changing solutions. Throughout the year, Regeneron empowers and supports employees to give back through our volunteering, pro bono, and matching gift programs. We are proud to be recognized on the Dow Jones Sustainability World Index and the Civic 50 list of the most "community-minded" companies in the United States.

    For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

    What is Society for Science?

    Society for Science is a champion for science, dedicated to promoting the understanding and appreciation of science and the vital role it plays in human advancement. Established in 1921, Society for Science is best known for its award-winning journalism through Science News and Science News Explores, its world-class science research competitions for students, including the Regeneron Science Talent Search, the Regeneron International Science and Engineering Fair, and the Thermo Fisher Scientific Junior Innovators Challenge, and its STEM Outreach programming that seeks to ensure that all students have an opportunity to pursue a career in STEM. A 501(c)(3) membership organization, Society for Science is committed to inform, educate, and inspire. Learn more at www.societyforscience.org and follow us on Facebook, X, Instagram, and LinkedIn.

    Media Contacts:

    Tina Parisi Tuttle, Regeneron 

    914-847-3511, tinaparisituttle@regeneron.com 

    Gayle Kansagor, Society for Science 

    703-489-1131, gkansagor@societyforscience.org



    Primary Logo

    Get the next $REGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $REGN

    DatePrice TargetRatingAnalyst
    1/7/2026$860.00Underperform → Buy
    BofA Securities
    12/3/2025$767.00Overweight → Equal-Weight
    Morgan Stanley
    11/24/2025$798.00Buy
    Truist
    11/24/2025$255.00Buy
    HSBC Securities
    11/13/2025$650.00Sector Perform
    Scotiabank
    8/14/2025$890.00Buy
    Rothschild & Co Redburn
    6/30/2025Buy → Hold
    Argus
    5/30/2025$662.00Outperform → Sector Perform
    RBC Capital Mkts
    More analyst ratings

    $REGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Zoghbi Huda Y exercised 1,638 shares at a strike of $376.69 and sold $1,279,812 worth of shares (1,638 units at $781.33) (SEC Form 4)

    4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

    2/23/26 4:55:58 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP Controller Pitofsky Jason sold $1,585,058 worth of shares (2,036 units at $778.52) and exercised 1,000 shares at a strike of $492.00, decreasing direct ownership by 20% to 4,272 units (SEC Form 4)

    4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

    2/11/26 4:03:58 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ryan Arthur F sold $77,853 worth of shares (100 units at $778.53), decreasing direct ownership by 0.56% to 17,803 units (SEC Form 4)

    4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

    2/11/26 4:02:23 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 20, 2022 - FDA Approves First Treatment for Eosinophilic Esophagitis, a Chronic Immune Disorder

    For Immediate Release: May 20, 2022 Today, the U.S. Food and Drug Administration approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in adults and pediatric patients 12 years and older weighing at least 40 kilograms (which is about 88 pounds). Today’s action marks the first FDA approval of a treatment for EoE. “As researchers and clinicians have gained knowledge about eosinophilic esophagitis

    5/20/22 3:11:09 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    SEC Filings

    View All

    SEC Form 13F-HR filed by Regeneron Pharmaceuticals Inc.

    13F-HR - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

    2/6/26 5:06:37 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Regeneron Pharmaceuticals Inc.

    10-K - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

    2/4/26 9:08:38 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

    1/30/26 6:51:21 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Press Release: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment

    Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged two to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chronic skin disease with underlying type 2 inflammation that can cause debilitating hives and recurring itch in young children Paris and Tarrytown, February 27, 2026. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of Dupixent (dupilumab) in the EU

    2/27/26 7:03:09 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment

    If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chronic skin disease with underlying type 2 inflammation that can cause debilitating hives and recurring itch in young children TARRYTOWN, N.Y. and PARIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of Dupixent® (dupilumab) in the European Union (EU) for the treatment of chronic spontane

    2/27/26 7:00:00 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders

    Key Takeaways: Regeneron will extend its title sponsorship of the Regeneron Science Talent Search (STS) for a second decade, continuing its partnership with Society for Science to support the United States' oldest and most prestigious science and mathematics competition for high school seniorsSince the start of Regeneron's sponsorship in 2017 through this year's STS, Regeneron and the Society have engaged and inspired more than 20,000 of the nation's top young scientists, recognized 3,000 as Regeneron scholars, and awarded over $31 million in prizesRegeneron is also the title sponsor of the Regeneron International Science and Engineering Fair (ISEF), a program of Society for Science and the

    2/26/26 12:00:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Regeneron Pharma upgraded by BofA Securities with a new price target

    BofA Securities upgraded Regeneron Pharma from Underperform to Buy and set a new price target of $860.00

    1/7/26 8:45:07 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron Pharma downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Regeneron Pharma from Overweight to Equal-Weight and set a new price target of $767.00

    12/3/25 8:30:10 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist resumed coverage on Regeneron Pharma with a new price target

    Truist resumed coverage of Regeneron Pharma with a rating of Buy and set a new price target of $798.00

    11/24/25 9:17:24 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Leadership Updates

    Live Leadership Updates

    View All

    Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization

    TARRYTOWN, N.Y., June 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the launch of a pioneering matching program for donations to Good Days, an independent national non-profit charitable organization, to support Good Days' Retinal Vascular and Neovascular Disease Fund. Through this initiative, Regeneron has committed to matching donations up to a total of $200 million at a one-to-one rate for the remainder of the 2025 calendar year, enabling more patients to affordably access essential medicines that help protect their vision. "We are proud to support Good Days with this unprecedented philanthropic effort," said Leonard Schleifer, M.D., Ph.D.,

    6/24/25 7:30:00 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs

    TARRYTOWN, N.Y., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio, Inc. to acquire full development and commercialization rights to its pipeline of investigational novel immune cell therapies, along with its discovery and clinical manufacturing capabilities. 2seventy bio employees who support the acquired programs will join Regeneron Cell Medicines, a newly formed research & development (R&D) unit to advance cell therapies and combination approaches in oncology and immunology. "Regeneron and 2seventy share a relentless commitment to push the boundaries of scie

    1/30/24 7:00:41 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

    NIH data show that globally less than 2% of genetic information being studied today originates from people of African ancestry1 The newly established Diaspora Human Genomics Institute (DHGI) will manage the Together for CHANGE initiative, which aims to increase available genomic data for people of African ancestry and enhance representation in STEM careers NASHVILLE, Tenn. and TARRYTOWN, N.Y. and WILMINGTON, Del. and BAGSVAERD, Denmark and BASEL, Switzerland, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Meharry Medical College, along with partners Regeneron Genetics Center® (RGC™), AstraZeneca, Novo Nordisk, and Roche, today announced the launch of the Together for CHANGE™ ("Changing Healthcare for

    10/18/23 9:00:00 AM ET
    $AZN
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Financials

    Live finance-specific insights

    View All

    Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026

    TARRYTOWN, N.Y., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2025 financial and operating results on Friday, January 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation

    1/2/26 4:05:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

    All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these responses are expected to deepen over time Across all dose groups, 95% (19 of 20 patients) of all evaluable VGPR+ patients achieved minimal residual disease negative status Data featured in an ASH oral presentation; LINKER-MM4 is the first clinical trial to evaluate a BCMAxCD3 bispecific monotherapy in NDMM and is part of a broad clinical development program evaluating Lynozyfic-based regimens in earlier lines of treatment Regeneron to host virtual ‘Regeneron Roundtable' investor event to dis

    12/7/25 4:30:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs

    Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a BCMAxCD3 bispecific antibody as a monotherapy in this setting Additional oral presentation spotlights data for odronextamab in combination with chemotherapy, without rituximab, as a frontline treatment for diffuse large B-cell lymphoma Other presentations span a broad range of hematologic conditions, including paroxysmal nocturnal hemoglobinuria and severe aplastic anemia Regeneron to host virtual ‘Regeneron Roundtable' investor event to discuss its multiple myeloma development program on Wednesday, December 10 at 8:30 a.m. ET TARRYTOWN, N.Y., Nov.

    11/13/25 7:00:00 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Regeneron Pharmaceuticals Inc. (Amendment)

    SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)

    2/13/24 5:12:22 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Regeneron Pharmaceuticals Inc. (Amendment)

    SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)

    2/9/24 6:19:03 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Regeneron Pharmaceuticals Inc. (Amendment)

    SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)

    2/9/24 9:49:31 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care